Drugs / AZD1446
AZD1446
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT01199315 | Sep → Dec 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01092299 | Feb → Jul 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01044342 | Dec 2009 → Apr 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01021189 | Dec 2009 → Jun 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00997308 | Oct → Dec 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00886067 | Apr → Aug 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00902993 | Apr → Sep 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00803855 | Dec 2008 → Apr 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01125683 | Jun 2010 → Mar 2011 | Alzheimer disease | AstraZeneca | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01039701 | Dec 2009 → Jul 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01012375 | Nov 2009 → Aug 2010 | attention deficit-hyperactivity disorder | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD1446 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01044342 ↗ |
| Known as | AZD1446 HCL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2179529 ↗ |
| Known as | TC-6683 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2179529 ↗ |
| Known as | TC6683 HCL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2179529 ↗ |
| Modality | Small molecule | — CHEMBL2179529 ↗ |
| Route | Oral | “oral, single dose” NCT00803855 ↗ |